Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
0:00
10:26
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More episodes from "The Lancet Respiratory Medicine in conversation with"
Don't miss an episode of “The Lancet Respiratory Medicine in conversation with” and subscribe to it in the GetPodcast app.